MHLW Updates Label To DPP-4 Diabetes Drugs
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare May 26 said it received 25 cases of adverse events reports in which a causal relation between taking dipeptidyl peptidase 4 inhibitor diabetes drug Januvia/Glactiv (sitagliptin) and hypoglycemia cannot be excluded